{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:33:50Z","timestamp":1794440030232,"version":"4.9.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Oxytocin administration during cesarean delivery is the first-line therapy for the prevention of uterine atony. Patients with preeclampsia may receive magnesium sulfate, a drug with known tocolytic effects, for seizure prophylaxis. However, no study has evaluated the minimum effective dose of oxytocin during cesarean delivery in women with preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>This study compared the effective dose in 90% population (ED90) of oxytocin infusion for achieving satisfactory uterine tone during cesarean delivery in nonlaboring patients with preeclampsia who were receiving magnesium sulfate treatment with a control group of normotensives who were not receiving magnesium sulfate. This prospective dual-arm dose-finding study was based on a 9:1 biased sequential allocation design. Oxytocin infusion was initiated at 13 IU\/h, on clamping of the umbilical cord, in the first patient of each group. Uterine tone was graded as satisfactory or unsatisfactory by the obstetrician at 4 minutes after initiation of oxytocin infusion. The dose of oxytocin infusion for subsequent patients was decided according to the response exhibited by the previous patient in the group; it was increased by 2 IU\/h after unsatisfactory response or decreased by 2 IU\/h or maintained at the same level after satisfactory response, in a ratio of 1:9. Oxytocin-associated side effects were also evaluated. Dose-response data for the groups were evaluated using a log-logistic function and ED90 estimates were derived from fitted equations using the delta method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The ED90 of oxytocin was significantly greater for the preeclampsia group (n = 27) than for the normotensive group (n = 40) (24.9 IU\/h [95% confidence interval {CI}, 22.4\u201327.5] and 13.9 IU\/h [95% CI, 12.4\u201315.5], respectively); the difference in dose requirement was 10.9 IU\/h (95% CI, 7.9\u201314.0;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). The number of patients with oxytocin-related hypotension, defined as a decrease in systolic blood pressure &gt;20% from baseline or to &lt;90 mm Hg, was significantly greater in the preeclampsia group (92.6% vs 62.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .030), while other side effects such as ST-T depression, nausea\/vomiting, headache, and flushing, were not significantly different. There was no significant difference in the need for additional uterotonic or uterine massage, estimated blood loss, and need for re-exploration for uncontrolled bleeding.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Patients with preeclampsia receiving preoperative magnesium therapy need a greater intraoperative dose of oxytocin to achieve satisfactory contraction of the uterus after fetal delivery, as compared to normotensives.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000005701","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:47:17Z","timestamp":1630504037000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Effective Dose of Prophylactic Oxytocin Infusion During Cesarean Delivery in 90% Population of Nonlaboring Patients With Preeclampsia Receiving Magnesium Sulfate Therapy and Normotensives: An Up-Down Sequential Allocation Dose-Response Study"],"prefix":"10.1213","volume":"134","author":[{"given":"Asha","family":"Tyagi","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology & Critical Care, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Mohan","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology & Critical Care, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvraj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology & Critical Care, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology & Critical Care, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devansh","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology & Critical Care, University College of Medical Sciences & Guru Teg Bahadur Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev Kumar","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Delhi Cancer Registry, Dr BR Ambedkar Institute-Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/AIA.0000000000000016","article-title":"Oxytocin protocols for cesarean delivery.","volume":"52","author":"Balki","year":"2014","journal-title":"Int Anesthesiol Clin"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12630-010-9297-1","article-title":"Up-down determination of the ED90 of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing cesarean delivery.","volume":"57","author":"George","year":"2010","journal-title":"Can J Anesth"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.AOG.0000191529.52596.c0","article-title":"Minimum oxytocin dose requirement after cesarean delivery for labor arrest.","volume":"107","author":"Balki","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/01.AOG.0000142709.04450.bd","article-title":"Oxytocin requirements at elective cesarean delivery: a dose-finding study.","volume":"104","author":"Carvalho","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/ALN.0000000000000682","article-title":"A randomized, double-blinded trial of a \u201crule of threes\u201d algorithm versus continuous infusion of oxytocin during elective cesarean delivery.","volume":"123","author":"Kovacheva","year":"2015","journal-title":"Anesthesiology"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1213\/ANE.0000000000000781","article-title":"The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study.","volume":"121","author":"Lavoie","year":"2015","journal-title":"Anesth Analg"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijoa.2010.05.001","article-title":"Oxytocin protocols during cesarean delivery: time to acknowledge the risk\/benefit ratio?","volume":"19","author":"Tsen","year":"2010","journal-title":"Int J Obstet Anesth"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12630-017-0867-3","article-title":"Effect of magnesium sulfate on oxytocin-induced contractility in human myometrium: an in vitro study.","volume":"64","author":"Onwochei","year":"2017","journal-title":"Can J Anaesth"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijoa.2013.11.004","article-title":"Relaxant effects of metoclopramide and magnesium sulfate on isolated pregnant myometrium: an in vitro study.","volume":"23","author":"Tang","year":"2014","journal-title":"Int J Obstet Anesth"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1067\/mob.2002.123897","article-title":"Magnesium sulfate inhibits the oxytocin-induced production of inositol 1,4,5-trisphosphate in cultured human myometrial cells.","volume":"187","author":"Hurd","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0002-9378(97)70558-1","article-title":"The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial.","volume":"176","author":"Witlin","year":"1997","journal-title":"Am J Obstet Gynecol"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R.","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJMoa021180","article-title":"A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.","volume":"348","author":"Belfort","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"e81959","DOI":"10.1371\/journal.pone.0081959","article-title":"Pre-eclampsia increases the risk of postpartum haemorrhage: a nationwide cohort study in the Netherlands.","volume":"8","author":"von Schmidt auf Altenstadt","year":"2013","journal-title":"PLoS One"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/00016340802613242","article-title":"Abnormal bleeding associated with preeclampsia: a population study of 315,085 pregnancies.","volume":"88","author":"Eskild","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9378(99)70041-4","article-title":"Effect of magnesium prophylaxis and preeclampsia on the duration of labor.","volume":"180","author":"Szal","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/bja\/ael302","article-title":"Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing caesarean section.","volume":"98","author":"Thomas","year":"2007","journal-title":"Br J Anaesth"},{"key":"R21-20250502","first-page":"386","article-title":"Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial.","volume":"98","author":"Munn","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijoa.2009.08.005","article-title":"Maternal haemodynamics at elective caesarean section: a randomised comparison of oxytocin 5-unit bolus and placebo infusion with oxytocin 5-unit bolus and 30-unit infusion.","volume":"19","author":"McLeod","year":"2010","journal-title":"Int J Obstet Anesth"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:29:11Z","timestamp":1786112951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000005701","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}